Investor Presentation Q1 2023

13 Investor presentation First three months of 2023 Financial results - First three months of 2023 Novo NordiskⓇ In DKK million Sales Gross profit Gross margin Sales and distribution costs Percentage of sales First three months of 2023 53,367 First three months of 2022 42,031 Change Change (reported) (CER) 27% 25% Research and development costs 45,185 84.7% (12,412) 23.3% (6,728) 35,114 29% 26% 83.5% (10,183) 22% 20% 24.2% (5,206) 29% 28% Percentage of sales 12.6% 12.4% Administration costs (1,071) (970) 10% 9% Percentage of sales 2.0% 2.3% Other operating income and expenses 33 392 (92%) (92%) Operating profit 25,007 19,147 31% 28% Operating margin 46.9% 45.6% Financial items (net) (270) (1,228) Profit before income tax 24,737 17,919 38% Income taxes (4,923) (3,709) 33% Effective tax rate 19.9% 20.7% Net profit 19,814 14,210 39% Diluted earnings per share (DKK) 8.78 6.22 41% CER: Constant exchange rates

View entire presentation